F&V Capital Management Buys Vertex Pharmaceuticals Shares

The investment firm added over 3,600 shares of the biotech company in Q4 2025.

Apr. 2, 2026 at 8:34am

Got story updates? Submit your updates here. ›

F&V Capital Management LLC bought a new stake of 3,645 shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) during the fourth quarter of 2025, according to the firm's latest 13F filing with the Securities and Exchange Commission. The new position was valued at approximately $1.65 million.

Why it matters

Vertex Pharmaceuticals is a leading biotech company focused on developing innovative treatments for serious diseases like cystic fibrosis. The company's portfolio of CFTR modulators has transformed standards of care for many CF patients. F&V Capital's investment signals confidence in Vertex's continued growth and pipeline potential.

The details

The new stake in Vertex Pharmaceuticals represents a strategic investment by F&V Capital Management, a Boston-based investment firm. In its 13F filing, the firm disclosed the purchase of 3,645 shares of the pharmaceutical company's stock during the fourth quarter of 2025.

  • F&V Capital Management bought the Vertex Pharmaceuticals shares in the fourth quarter of 2025.

The players

F&V Capital Management LLC

A Boston-based investment firm that bought a new stake in Vertex Pharmaceuticals in Q4 2025.

Vertex Pharmaceuticals Incorporated

A Boston-based biotechnology company focused on developing innovative treatments for serious diseases like cystic fibrosis.

Got photos? Submit your photos here. ›

The takeaway

F&V Capital's investment in Vertex Pharmaceuticals reflects the biotech company's strong position in the cystic fibrosis treatment market and its promising pipeline of future therapies. As Vertex continues to innovate and expand its reach, the firm's strategic stake could signal further growth opportunities for the company.